IVF clinic silenced couple who discovered donor mix-up when baby was born | 7.30

Key Concepts:

• IVF mix-up
• Donor sperm
• Double witnessing
• Reproductive Technology Accreditation Committee (RTAC)
• Non-disclosure agreement (NDA)
• Transparency and accountability
• Adverse event reporting
• Governance and disclosure
• Risk management
• Sperm bank audits

I. The IVF Mix-Up Incident

• A Brisbane couple using Queensland Fertility Group (QFG), owned by Vertus Health, had an IVF baby using the woman's eggs and donor sperm from the Seattle Sperm Bank.
• The child's appearance differed significantly from what was expected based on the chosen donor profile (Caucasian), raising concerns about a mix-up.
• The clinic initially dismissed the couple's concerns, denying any error.
• An internal investigation by Vertus Health revealed that the Seattle Sperm Bank had mixed up samples from a Caucasian donor and an African-American Nigerian donor due to two men donating on the same day.
• The couple was given money and signed a strict non-disclosure agreement (NDA) to remain silent about the incident.
• A family friend revealed the details before the NDA was signed.

II. Lack of Due Diligence and Double Witnessing

• The investigation found that a crucial identity check, known as "double witnessing," was nonexistent during collections at the US sperm bank.
• Double witnessing, standard in Australia since 2012, involves a second person verifying the details of a patient or individual undergoing an IVF procedure to prevent mistakes.
• Dr. Fab Hor, an embryologist, emphasized the increased risk of errors in clinics that do not implement double witnessing.
• The Seattle Sperm Bank has since implemented a seven-step double verification process.
• QFG stated that all remaining sperm from the implicated donor was destroyed.

III. Regulatory Oversight and Reporting Failures

• Using the wrong sperm is classified as a "severe notifiable adverse event" that must be reported to the industry regulator, the Reproductive Technology Accreditation Committee (RTAC).
• RTAC confirmed that no report was filed regarding the QFG incident.
• At the time, there was no requirement to make such a report.
• RTAC is under scrutiny for its effectiveness as a regulator, as it is funded by the IVF industry.
• Karen Hammerberg, a fertility researcher, expressed concern about the industry's lack of transparency and accountability.

IV. Corporate Governance and Disclosure

• As a publicly listed company at the time, Vertus Health had disclosure obligations to its shareholders regarding risks and incidents.
• Shareholders need to be informed about company risks and have confidence that issues are resolved effectively.
• Vertus Health stated that they do not believe the former board and management engaged in a cover-up.

V. Ongoing Risks and Audits

• Six years after the initial incident, an audit revealed that four of Vertus Health's international sperm providers were still high risk for mix-ups due to the lack of double witnessing.
• QFG was the only Australian clinic also failing to perform these identity checks.
• Despite the audit findings, QFG did not take action to minimize the risk for its patients for another three years.
• In 2023, QFG finally started checking the identities of thousands of frozen sperm samples.
• The results showed that 99% of local sperm frozen before 2020 was deemed high risk of not being the person on the label.

VI. Current Legal Action and Industry Review

• Anastasia Gun is suing Queensland Fertility Group for mixing up two of its own sperm donors, resulting in two of her three children having a different biological father than intended.
• QFG refuses to acknowledge any wrongdoing.
• A rapid review of Australia's fertility industry is currently underway.

VII. Conclusion

The investigation reveals a significant IVF mix-up incident at Queensland Fertility Group, highlighting failures in sperm bank procedures, regulatory oversight, and corporate governance. The lack of double witnessing, failure to report the adverse event, and delayed action to address ongoing risks raise serious concerns about patient safety and industry accountability. The ongoing legal action and industry review underscore the need for greater transparency and stricter regulations to prevent future incidents and protect families undergoing fertility treatment.